• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真性红细胞增多症:综述

Polycythemia vera: a review.

作者信息

Golden Christy

出版信息

Clin J Oncol Nurs. 2003 Sep-Oct;7(5):553-6. doi: 10.1188/03.CJON.553-556.

DOI:10.1188/03.CJON.553-556
PMID:14603552
Abstract

Polycythemia vera (PV) is a clonal stem cell disorder characterized by increased erythrocyte production. Its etiology is not fully understood, and hemorrhage, thrombosis, and hyperviscosity may occur at any time during the course of this disorder. Treatment depends on the most affected cell type, duration and severity of the condition, and patient age. PV treatment can involve phlebotomy, administration of myelosuppressive agents, and biologic therapy. The inconsonant nature of the disease and complications related to its various treatments present nursing care challenges. Nurses must work with patients with PV to ensure compliance with treatment, teach awareness of disease- and treatment-related complications, and provide needed support.

摘要

真性红细胞增多症(PV)是一种以红细胞生成增加为特征的克隆性干细胞疾病。其病因尚未完全明确,在该疾病过程中的任何时候都可能发生出血、血栓形成和血液黏稠度增加。治疗取决于受影响最严重的细胞类型、病情的持续时间和严重程度以及患者年龄。PV的治疗可包括放血、给予骨髓抑制药物和生物治疗。该疾病的不一致性以及与其各种治疗相关的并发症带来了护理挑战。护士必须与PV患者合作,以确保其遵守治疗方案,教授对疾病和治疗相关并发症的认识,并提供所需的支持。

相似文献

1
Polycythemia vera: a review.真性红细胞增多症:综述
Clin J Oncol Nurs. 2003 Sep-Oct;7(5):553-6. doi: 10.1188/03.CJON.553-556.
2
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.基于真性红细胞增多症研究组方案的真性红细胞增多症治疗建议。
Semin Hematol. 1986 Apr;23(2):132-43.
3
Diagnosis and therapy of polycythemia vera.真性红细胞增多症的诊断与治疗
Semin Thromb Hemost. 2006 Apr;32(3):267-75. doi: 10.1055/s-2006-939438.
4
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.真性红细胞增多症、原发性血小板增多症和骨髓纤维化伴髓样化生患者接受羟基脲治疗的白血病发生风险。
Am J Hematol. 1996 May;52(1):42-6. doi: 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6.
5
[Efficacious treatment of a fatal blood disease: polycythemia vera].[一种致命血液疾病——真性红细胞增多症的有效治疗方法]
Sangre (Barc). 1997 Jun;42(3):215-8.
6
Neurologic complications of polycythemia and their impact on therapy.真性红细胞增多症的神经系统并发症及其对治疗的影响。
Oncology (Williston Park). 1990 Mar;4(3):59-64; discussion 64-6.
7
Polycythemia vera.真性红细胞增多症
Am Fam Physician. 2004 May 1;69(9):2139-44.
8
Cardiovascular events and intensity of treatment in polycythemia vera.原发性骨髓纤维化患者的心血管事件和治疗强度。
N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.
9
Evaluation of arterial compliance in polycythemia vera patients: short and long-term influence of phlebotomy.真性红细胞增多症患者动脉顺应性的评估:放血疗法的短期和长期影响
Isr Med Assoc J. 2006 Dec;8(12):845-7.
10
Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.真性红细胞增多症患者的风险分层、分期及治疗:意大利与欧洲关于真性红细胞增多症低剂量阿司匹林数据的合作
Semin Thromb Hemost. 2006 Apr;32(3):276-82. doi: 10.1055/s-2006-939439.

引用本文的文献

1
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.肝素和共价抗凝血酶-肝素复合物对红细胞凝血酶原酶复合物的抑制作用。
J Biochem. 2013 Jan;153(1):103-10. doi: 10.1093/jb/mvs129. Epub 2012 Oct 24.